HLB Pharmaceutical Co. Ltd (047920) — Cash Flow Quality Index
HLB Pharmaceutical Co. Ltd (047920) has a Cash Flow Quality Index of -0.68x as of March 2025. Operating cash flow of ₩-1.07 Billion is below net income of ₩1.57 Billion, suggesting accrual-heavy earnings not yet converted to cash. Explore how much of HLB Pharmaceutical Co. Ltd's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
HLB Pharmaceutical Co. Ltd Cash Flow Quality Index (2014–2024)
Historical Cash Flow Quality Index for HLB Pharmaceutical Co. Ltd across 4 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check 047920 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Annual Cash Flow Quality Index for HLB Pharmaceutical Co. Ltd (2014–2024)
Year-by-year earnings quality comparison for HLB Pharmaceutical Co. Ltd. For live market cap and the full company financial profile, see HLB Pharmaceutical Co. Ltd (047920) total market value.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 3.39x | ₩6.84 Billion | ₩2.02 Billion | ▲ +18.3% |
| 2019 | 2.86x | ₩1.35 Billion | ₩472.66 Million | ▲ +875.8% |
| 2016 | -0.37x | ₩-213.11 Million | ₩577.41 Million | ▼ -107.3% |
| 2014 | 5.06x | ₩1.54 Billion | ₩304.58 Million | — |